Researchers are testing a drug combination of TAS-102, an approved drug for colorectal cancer, and nanoliposomal irinotecan, on gastrointestinal cancers.
Wasting, or cachexia, is the focus of a clinical trial testing a cachexia immunotherapy treatment combined with standard pancreatic cancer treatment.
A clinical trial compares standard chemotherapy with and without the addition of a PARP inihibitor, for patients whose pancreatic cancer is spreading again.
A clinical trial compares the effectiveness of low-dose continuous chemotherapy with and without high doses of vitamin C.
Onivyde (injectable irinotecan), combined with fluorouracil and leucovorin, has been approved as a second-line treatment for advanced pancreatic cancer.